Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Novartis
Galapagos NV
AvenCell Therapeutics, Inc.
Eli Lilly and Company
Caribou Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
Autolus Limited
Medical University of South Carolina
Children's Hospital Medical Center, Cincinnati
Mayo Clinic
National Research Center for Hematology, Russia
Baylor College of Medicine
Eli Lilly and Company
AstraZeneca
Gilead Sciences
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Wondercel Biotech (ShenZhen)
National Institutes of Health Clinical Center (CC)
Umoja Biopharma
Fred Hutchinson Cancer Center
Grit Biotechnology
University Hospital, Basel, Switzerland
Thomas Helleday Foundation
British Columbia Cancer Agency
University of Pennsylvania
Fate Therapeutics
Miltenyi Biomedicine GmbH
CRISPR Therapeutics
Medical College of Wisconsin
Case Comprehensive Cancer Center
AVM Biotechnology Inc
Pharmacyclics Switzerland GmbH
CRISPR Therapeutics
Mayo Clinic
Mayo Clinic
City of Hope Medical Center
University of Maryland, Baltimore
Boryung Pharmaceutical Co., Ltd
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Assistance Publique - Hôpitaux de Paris
Nationwide Children's Hospital
Essen Biotech
Roswell Park Cancer Institute
Baylor College of Medicine